Article Text

Download PDFPDF
Undertreating cardiovascular disease in people with chronic obstructive pulmonary disease (COPD)
  1. Andrea S Gershon1,2,3,4,
  2. Alina Blazer2,
  3. Dennis Ko1,3,4
  1. 1Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  2. 2Division of Respirology, University of Toronto Department of Medicine, Toronto, Ontario, Canada
  3. 3Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
  4. 4ICES, Toronto, Ontario, Canada
  1. Correspondence to Dr Andrea S Gershon, Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada; andrea.gershon{at}ices.on.ca

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death globally following ischaemic heart disease and stroke.1 Cardiovascular disease (CVD) is one of the most common comorbidities experienced by people with COPD and is a leading cause of death. People with COPD account for about 40% of all cardiovascular hospitalisations.2 3 This is believed to be because of the direct effects of COPD on CVD, for example, by causing generalised inflammation that affects the heart, as well as shared common risk factors, such as smoking. Thus, prevention and management of CVD should be a high priority in the COPD population.

Reducing CVD risk can be done by managing modifiable risk factors such as smoking, hypertension and dyslipidaemia. The foundation for the primary prevention of CVD is CVD risk stratification, with guidelines recommending treatment with statins and antihypertensives in people who surpass a threshold risk, thereby gaining more benefits from those treatments than harms.4 Risk is calculated based on general population estimates but is revised upwards where certain risk-enhancing clinical factors are present, resulting in more people with those factors being treated. These risk-enhancing clinical factors include diseases …

View Full Text

Footnotes

  • Contributors All authors contributed to the editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles